Precision medicine relies on understanding how differences affect drug response. Researchers can develop more precise treatments that are effective for more patients when prioritizing diversity.
Manufacturing proteins is notoriously expensive and complex. Will new ways of producing them come from continuous processes, Sunflowers, or even…goat milk?
Useful therapeutic products and ideas are everywhere, yet limited by the ability to actually produce them in needed quantitites. The technologies from Sunflower® Therapeutics enable bioprocess applications throughout the globe in a deployable unit with a small footprint. Dr. Kerry Love describes the technology and it’s applications, along with the philosophy of a public benefit corporation that seeks to meet the needs from small startups to remote ressearchers.
Helping local students find a love of science that can translate into high-paying jobs. That’s the goal of a program spun out of MIT that’s gaining traction in high schools across the country. BioBuilder helped a Malden native earn a new job in the biotech industry.
New and emerging technologies offer cheaper modes of manufacture – here’s how and why the world’s less wealthy countries could seize the moment
As distinctions between upstream and downstream operations fade, manufacturing facilities are becoming more compact, accessible, and sustainable.
Distributed manufacturing is among the hottest trends in biomanufacturing. Here, GEN talks to Laura Crowell, PhD, director of research & development at Sunflower® Therapeutics about bringing protein manufacturing to the benchtop in low- and middle-income countries.
Today, vaccines and other protein-based biologic drugs are typically made in large, dedicated manufacturing facilities. But that doesn’t always fit the need, and it could one day change. A team of researchers has engineered a miniaturized biopharmaceutical “factory” that could fit on a dining room table and produce hundreds to thousands of doses of a needed treatment in about three days.
Today there’s essentially one model for drug production: make as much as possible. But J. Christopher Love, a professor of chemical engineering at the Massachusetts Institute of Technology, has spent the last five years pursuing a different vision: a desktop drug manufacturing process that would be fast and nimble enough to help combat a small disease outbreak, treat an unusual cancer, or replace a rare enzyme.
An all-in-one bench-top system can churn out hundreds or thousands of doses of a medically useful protein in a few days — and can easily switch to manufacturing other proteins.